Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
IPO Year: 2016
Exchange: NASDAQ
Website: syndax.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $37.00 | Buy | UBS |
| 6/28/2024 | $37.00 | Buy | Jefferies |
| 1/31/2024 | $36.00 → $23.00 | Sector Outperform → Sector Perform | Scotiabank |
| 12/22/2023 | $45.00 | Buy | Mizuho |
| 10/25/2023 | $29.00 | Buy | BofA Securities |
| 10/11/2023 | $30.00 | Buy | Goldman |
| 7/27/2023 | Sector Outperform | Scotiabank | |
| 7/11/2023 | $40.00 | Buy | Guggenheim |
| 4/17/2023 | $34.00 | Buy | BTIG Research |
| 1/31/2023 | $37.00 | Buy | Stifel |
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
10-Q - Syndax Pharmaceuticals Inc (0001395937) (Filer)
8-K - Syndax Pharmaceuticals Inc (0001395937) (Filer)
DEFA14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)
DEF 14A - Syndax Pharmaceuticals Inc (0001395937) (Filer)
SCHEDULE 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
144 - Syndax Pharmaceuticals Inc (0001395937) (Subject)
S-8 - Syndax Pharmaceuticals Inc (0001395937) (Filer)
– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alt
– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its finan
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section o
– Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2 R/R mNPM1 AML cohort – – 100% ORR (37/37) and 95% CRc (35/37) in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML – – BEAT AML data highlight the potential for revumenib to advance the current standard of care – WALTHAM, Mass., Dec. 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company develop
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – – 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – – Responses were rapid, durable and observed across all major subgroups in expanded dataset ofPh 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 – – Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting – WALTHAM, Mass.
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therap
– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population – – Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events – – Results highlight consistency of revumenib's compelling clinical profile – – sNDA filing in R/R mNPM1 AML expected in 1H25, pending anticipated FDA approval of revumenib in R/R KMT2Ar acute leukemia in 4Q24 – – Syndax to host a conference call today at 8:00 am ET – WALTHAM, Mass., Nov. 12, 2024 /PRNew
– New revumenib and Niktimvo™ clinical data will be highlighted at 66th ASH Annual Meeting – – mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 – – Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – – $350 million royalty funding agreement for Niktimvo expected to fund Company through profitability – – Company to host a conference call today at 4:30 p.m. ET – WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax
WALTHAM, Mass., Oct. 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2024 financial results and provide a business update on Tuesday, November 5, 2024. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, November 5, 2024 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's we
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET. A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.synd
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial – NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that multiple abstracts showcasing clinical data for Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) were accepted for presentation at the 30th European Hematology Associatio
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m. PT/ 12:20 p.m. ET.TD Cowen 6th Annual Oncology Innovation Summit with a virtual fireside chat on Wednesday, May 28, 2025, at 10:30 a.m. ET. A live webcast of the fireside chats will be available in the Investor section o
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 – NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) have been published in
– $20.0 million in Revuforj® (revumenib) net revenue in first full quarter of launch – – $13.6 million in Niktimvo™ (axatilimab-csfr) net revenue (reported by Incyte) in first partial quarter of launch – – Submitted sNDA for revumenib in R/R mNPM1 AML – – Initiated a pivotal frontline trial of revumenib plus ven/aza in mNPM1 and KMT2Ar AML – – $602.1 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda
NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2025 the Company granted inducement awards to purchase up to 188,100 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates. About Syn
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial results and provide a business update on Monday, May 5, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, May 5, 2025 to discuss the Company's financial results and provide a business update. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alt
NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2025 the Company granted inducement awards to purchase up to 50,000 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceuti
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
3 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
UBS initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
Jefferies initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
Scotiabank downgraded Syndax Pharmaceuticals from Sector Outperform to Sector Perform and set a new price target of $23.00 from $36.00 previously
Mizuho initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $45.00
BofA Securities initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $29.00
Goldman initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $30.00
Scotiabank initiated coverage of Syndax Pharmaceuticals with a rating of Sector Outperform
Guggenheim initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $40.00
BTIG Research resumed coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $34.00
Stifel initiated coverage of Syndax Pharmaceuticals with a rating of Buy and set a new price target of $37.00
Submission status for SYNDAX PHARMACEUTICALS INC's drug REVUFORJ (ORIG-1) with active ingredient REVUMENIB has changed to 'Approval' on 11/15/2024. Application Category: NDA, Application Number: 218944, Application Classification: Type 1 - New Molecular Entity
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G/A - Syndax Pharmaceuticals Inc (0001395937) (Subject)
SC 13G - Syndax Pharmaceuticals Inc (0001395937) (Subject)
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) and Chief Medical Officer. Dr. Botwood brings to Syndax over 25 years of industry experience, most recently serving as the Head of Worldwide Medical Oncology at Bristol Myers Squibb, where he oversa
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex
WALTHAM, Mass., May 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Aleksandra Rizo, M.D., Ph.D., to its Board of Directors. Dr. Rizo has extensive clinical development experience and a track record of successfully leading the development of several hematology drugs from discovery through commercialization. She will serve as a member of the Science and Technology Committee of the Board. Dr. Rizo will replace Dr. Briggs Morrison who will step down effective May 14, 2024 after a successful 9-year tenure as a member of the Company's Board of Directo
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. "Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company's development and growth," said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. "His exp
– Steven Closter brings more than 30 years of commercial experience in the biopharmaceutical industry to Syndax – – Company on track for two potential first- and best-in-class product launches in 2024 – WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately. Mr. Closter will lead the Company's commercial strategy and operations, including marketing, sales, and market access, succeeding Steve Sabus, who is departing for personal reasons. "Steven Closter is an accompl
- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer - WALTHAM, Mass., March 30, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Neil Gallagher, M.D., Ph.D., to the role of President, Head of Research and Development (R&D), effective April 10, 2023. Dr. Gallagher brings to Syndax over 20 years of industry experience, most recently serving as Chief Medical Officer, Vice President, Head of Development at AbbVie, where he led multiple development programs through approval globally and over
WALTHAM, Mass., Dec. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5, 2022. Mr. Sabus brings to Syndax more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry. As Chief Commercial Officer, Mr. Sabus will oversee all commercial functions, including the development of critical launch initiatives, sales planning and commercial strategy. "Steve is an accomplished executive who has laun
WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Goldan to the role of Chief Financial Officer, effective immediately. Mr. Goldan, who brings to Syndax nearly thirty years of leadership and operational experience at several pharmaceutical, biotechnology, and medical technology companies, most recently served as Chief Financial Officer at Optinose®, where he helped build the infrastructure to support the launch of XHANCE® (fluticasone propionate) in the United States. As Chief Fi
WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately. Dr. Madigan, who brings to Syndax over 20 years of clinical hematology expertise and broad experience in the design and execution of early to late-stage clinical programs across oncology and rare diseases, will lead the Company's clinical development strategy. She will succeed Michael Meyers, M.D., Ph.D., who will continue with the Company through June before
Company expands leadership team across business and science as it advances precision oncology pipeline Flare Therapeutics, a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Daphne Karydas as Chief Operating Officer and Chief Financial Officer, and Michaela Bowden, PhD, as Senior Vice President of Biology and Translation. "We are thrilled to be growing Flare's executive team with the appointment of these two outstanding and accomplished industry leaders, deepening our expertise in areas of business and science and positioning Flare for growth," said Abbie Celniker, PhD, interim Chief Exe